掲示板「みんなの評価」
- 強く買いたい
- 買いたい
- 様子見
- 売りたい
- 強く売りたい
直近1週間でユーザーが掲示板投稿時に選択した感情の割合を表示しています。
- このスレッドは終了し、閲覧専用となっています。
- コメントの投稿、最新コメントの閲覧はこちらの最新スレッドをご利用ください。
掲示板のコメントはすべて投稿者の個人的な判断を表すものであり、
当社が投資の勧誘を目的としているものではありません。
-
1573(最新)
あほが、馬鹿な事、書いたんだろう
気にするなっ -
1572
嘘かも知れんな
-
1571
2016年4月4日 – Heptares治療学(「Heptares」)そーせいG社の全面子会社
4つの製薬会社(Astex Pharmaceuticals、アストラゼネカ、グラクソ・スミスクラインとUCB)と組んだと発表します。
とtwitterに書いてあるんだけどどういうこと?? -
1570
@AAAsu_ka: 2016年4月4日 – Heptares治療学(「Heptares」)そーせいG社の全面子会社
4つの製薬会社(Astex Pharmaceuticals、アストラゼネカ、グラクソ・スミスクラインとUCB)と組んだと発表します。
https://t.co/ZcBPLv39rg
これまじ? -
1568
Heptares治療学(「Heptares」)そーせいG社の全面子会社
4つの製薬会社(Astex Pharmaceuticals、アストラゼネカ、グラクソ・スミスクラインとUCB)と組んだと発表します。
https://t.co/ZcBPLv39rg
まじ!? -
とても楽しみなことになってきた。
-
FEI Partners with Five Pharmaceutical Companies, the Medical Research Council and the University of Cambridge to form Cryo-EM Research Consortium
Organizations involved in the Cambridge Pharmaceutical Cryo-EM Research Consortium will share access to cryo-electron microscopy equipment and methods and will collaborate on developing the technology to benefit pharmaceutical drug discovery research.
HILLSBORO, Ore. and LONDON, April 04, 2016 (GLOBE NEWSWIRE) -- FEI (NASDAQ:FEIC) has partnered with five pharmaceutical companies: Astex Pharmaceuticals, AstraZeneca, GlaxoSmithKline, Heptares Therapeutics, and UCB; the Medical Research Council Laboratory of Molecular Biology (MRC-LMB); and the University of Cambridge's Nanoscience Centre, to form the "Cambridge Pharmaceutical Cryo-EM Consortium," which is the first of its kind worldwide. As part of the three-year agreement, FEI will provide sample preparation and data collection services on a Titan Krios(TM) cryo-transmission electron microscope (cryo-EM) to the consortium companies for early-stage drug discovery research.
The five companies involved in the consortium will share access to the microscope with colleagues from the MRC-LMB and the University of Cambridge in return for expert guidance on the use of cryo-EM technology. FEI's Titan Krios will be installed at the Nanoscience Centre in May.
Richard Henderson, pioneer in the field of cryo-EM at MRC-LMB, states, "It is delightful to know that the development of cryo-EM, which many people have worked on for many years, has now reached mainstream structural biology. It is particularly satisfying that pharmaceutical companies are keen to evaluate the approach for drug development."
Prof. Sir Mark Welland, director of the Nanoscience Centre, said, "This is a great opportunity for researchers across the University to access a state-of-the-art microscope."
Cryo-EM has quickly become one of the most important techniques used by structural biologists today to obtain molecular-scale three-dimensional (3D) information about protein structures. When combined with traditional methods for structure determination, such as x-ray crystallography and nuclear magnetic resonance spectroscopy, the resulting models can reveal the structure of complex, dynamic molecular assemblies down to the scale of individual atoms. The consortium's Titan Krios will use the Relion software package, developed by Sjors Scheres at MRC-LMB, to process the image data into a visual 3D model that helps researchers see and understand the structure and function of the protein.
"Cryo-EM 3D models allow us to see and understand the workings of protein-based molecular machines that we could not analyze before because they were too large and complex or were resistant to the preparations required for other techniques," states Peter Fruhstorfer, vice president and general manager of the Life Sciences business, FEI. "The technique was rapidly adopted by leading academic researchers and is now finding its way into early stage discovery and development in the pharmaceutical industry."
Fruhstorfer adds, "In addition to installing the Titan Krios cryo-EM system, our contribution to the consortium includes providing an application scientist that will work with the participating companies to ensure a smooth workflow throughout, from sample preparation to data collection and data processing, with a special focus on creating a standardized and robust single-particle analysis workflow." -
追証間際のやつがいる
眠れない夜を過ごすのだろう -
寄り天だな
富士山チャートかもな
好きなほうを選べ -
1562
しつこい男は嫌いよ!、ー女は嫌いだ!かな? ぐらいは言えないとね。
これを教訓に転生して、別人になりましょうね~♡ -
1559
ちなみにMRC-LMB関連のEventは(済)となりましたが、
"THE POTENTIAL OF SYNTHETIC BIOLOGY TO ENHANCE HUMAN HEALTH"
March 22, 2016
Chris Tate, MRC Laboratory of Molecular Biology,Cambridge, United Kingdom
Chris Tate has spent over 25 years working on integral membrane proteins from bacteria to humans to understand how they translocate signals, ions or solutes across the membrane.
For the past 10 years his group at the Laboratory of Moelcular Biology (Cambridge, UK) has been working extensively on the structure determination of G protein coupled receptors,
which has led to a molecular understanding of how they are activated upon binding agonists and why ligands of slightly different structures show dramatic diffrences in their efficacy.
The methodology of conformational thermostabilisation was developed in his lab and this was used as the technological foundation for the spin-out company Heptares Therapeutics that Tate helped to co-found in July 2007.
Heptares has grown into a world-leading drug discovery biotech company that uses structure-based drug design to develop new therapeutics that are now entering the clinic. -
1558
まだまだ上がって、当然でしょ
-
1557
売る人が普通、そんなこと言わへんで~。 ジンセイノ無駄遣い。大事な命の無駄遣い。
全て無駄遣いですね~(°∀°) -
1556
明日も円高で、日経は下げそうですね。
信用買いで膨らんでるから、
売りで逃げる人達が出ますねー -
1554
マネパG8732
伊勢志摩サミットにらみ再脚光
今年5月下旬に開催される伊勢志摩サミットではテロ資金対策が主要議題となる見込みで、これを視野に政府も法改正を急いだという背景がある。日本は法整備で相対的に出遅れていたが、ここ官民を挙げての動きがビットコイン関連に再度、光を当てる流れにある。 -
1551
mei***** 強く買いたい 2016年4月5日 01:07
もっと株価を上げろ!
-
1550
*** 2016年4月5日 01:06
>とりあえず文章をコピーをしといて何度でも投稿できるようにしておけば
以前試しに消された内容を繰り返し書き込みしたら、しばらく投稿できなくなったことがある。
判断してるのが、人か機械かは不明。 -
1549
機関は日経暴落を盾にしてこれでもかってくらい落としてきますからね・・・
冗談抜きでマイナス2,000とかありえますよ -
1547
明日は14,000円割れるところまで落としてくる可能性は高いですね
残念ですが私はおそらく明日手放すことになると思います -
1544
FEI PARTNERS WITH FIVE PHARMACEUTICAL COMPANIES, THE MEDICAL RESEARCH COUNCIL AND THE UNIVERSITY OF CAMBRIDGE TO FORM CRYO-EM RESEARCH CONSORTIUM
HILLSBORO, Ore. and LONDON, April 04, 2016 -- FEI (NASDAQ:FEIC) has partnered with five pharmaceutical companies:
Astex Pharmaceuticals, AstraZeneca, GlaxoSmithKline, Heptares Therapeutics, and UCB; the Medical Research Council Laboratory of Molecular Biology (MRC-LMB);
and the University of Cambridge’s Nanoscience Centre, to form the “Cambridge Pharmaceutical Cryo-EM Consortium,” which is the first of its kind worldwide.
As part of the three-year agreement,
FEI will provide sample preparation and data collection services on a Titan Krios™ cryo-transmission electron microscope (cryo-EM) to the consortium companies for early-stage drug discovery research.
The five companies involved in the consortium will share access to the microscope with colleagues from the MRC-LMB and the University of Cambridge in return for expert guidance on the use of cryo-EM technology.
FEI’s Titan Krios will be installed at the Nanoscience Centre in May.
Richard Henderson, pioneer in the field of cryo-EM at MRC-LMB, states,
"It is delightful to know that the development of cryo-EM, which many people have worked on for many years, has now reached mainstream structural biology.
It is particularly satisfying that pharmaceutical companies are keen to evaluate the approach for drug development."
・・・
読み込みエラーが発生しました
再読み込み